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Background and purpose: Acute ischemic stroke treatment with intravenous
thrombolysis (IVT) is restricted to a time window of 4.5 h after known or presumed
onset. Recently, magnetic resonance imaging-guided treatment decision-making in
wake-up stroke (WUS) was shown to be effective. The aim of this study was to
determine the safety and outcome of IVT in patients with a time window beyond
4.5 h selected by computed tomography perfusion (CTP) imaging.
Methods: We analyzed all consecutive patients last seen well beyond 4.5 h
after stroke onset treated with IVT based on CTP between January 2015 and
October 2018. CTP was visually assessed to estimate the mismatch between
cerebral blood flow and cerebral blood volume maps. Early infarct signs were
documented according to Alberta Stroke Program Early CT Score
(ASPECTS). Safety data were obtained for mortality and symptomatic intrac-
erebral hemorrhage (sICH). Follow-up was assessed with the modified Rankin
Scale (mRS).
Results: A total of 70 patients fulfilled the inclusion criteria (mean age  SD
77.6  11.5 years, 50.0% female). Median National Institutes of Health
Stroke Scale score on admission was 8.0 [interquartile range (IQR), 4–14]. The
most frequent reasons for an extended time window were WUS (60.0%) and
delayed hospital admission (27.1%). Median time from last seen well to IVT
was 11.4 h. Median ASPECTS was 10 (IQR, 9–10) and CTP mismatch 90%
(IQR, 80%–100%). A total of 24 patients (34.3%) underwent additional
mechanical thrombectomy. sICH occurred in four patients (5.7%). At follow-
up, 49.3% had an mRS score of 0–2 and 22.4% had an mRS score of 0–1.
Conclusions: In patients presenting in an extended time window beyond
4.5 h, IVT treatment with decision-making based on CTP might be a safe pro-
cedure. Further evaluation in clinical trials is needed.
Introduction
The burden of acute ischemic stroke remains high
despite all recent advances in acute therapy using
intravenous thrombolysis (IVT) and mechanical
thrombectomy (MT) [1]. Early treatment is associated
with better clinical outcome [2,3]. The main reason for
withholding IVT is an unknown time of onset and last
seen well >4.5 h ago or a proven onset of symptoms
>4.5 h ago [4,5]. Therefore, the majority of patients who
wake up with stroke symptoms beyond 4.5 h of pre-
sumed symptom onset [‘wake-up stroke’ (WUS)] and
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patients with unknown symptom onset and a last seen
well >4.5 h ago do not receive IVT. This is the case in
up to 14–27% of acute stroke patients [6,7]. A substan-
tial proportion of strokes that are evident after sleep
probably occur within the last few hours before awaken-
ing, which would be within the approved time window
for IVT [8]. As a result, in a significant proportion of
patients effective therapeutic options might be withheld,
e.g. in the EXTEND-IA trial, only 13.4% of patients
were treated with IVT, mostly because of an extended
time window [9]. However, real-world data from the
nationwide Austrian Stroke Unit Registry compared in
a non-randomized study the safety and efficacy of IVT
in WUS and known onset of symptoms in stroke
patients. There was no statistical difference regarding
clinical outcome and complication rate [10]. These reg-
istry data do not fully reveal the selection parameters
for IVT in these patients. Different modalities for
penumbral imaging that guides patient selection for
reperfusion therapy were investigated [6,11–13]. The
WAKE-UP trial demonstrated a significantly better
functional outcome in patients with extended time win-
dow and IVT decision-making guided by diffusion-
weighted imaging and fluid-attenuated inversion recov-
ery mismatch in magnetic resonance imaging (MRI)
compared with placebo [14]. The recently published
EXTEND trial showed a benefit of IVT in an extended
time window of up to 9 h after symptom onset and
WUS patients using penumbral imaging with MRI or
computed tomography perfusion (CTP) [15]. Results of
DAWN and DEFUSE 3 trials showed a benefit of MT
in patients with an unknown symptom onset, severe
stroke and large-vessel occlusion [16,17]. However, in
clinical practice, a large number of patients do not
receive IVT due to extended time window and unavail-
ability of functional neuroimaging in many hospitals,
especially with limited or no access to MRI [18]. Fur-
thermore, MRI is more time-consuming than CTP,
which has practical advantages in 24/7 accessibility and
fewer practical restrictions compared with MRI. Here,
we present a retrospective analysis of prospectively col-
lected data on imaging and clinical outcome of patients
treated with IVT in an extended time window of >4.5 h
in WUS patients and patients with unknown time of




Between January 2015 and October 2018, all consecu-
tive patients treated with IVT in our tertiary compre-
hensive stroke center were prospectively collected.
Patients with extended time window were included
in cases of: (i) WUS and last seen well >4.5 h ago, (ii)
unknown symptom onset with last seen well >4.5 h
ago and (iii) known symptom onset >4.5 h ago. Treat-
ment decisions were made by experienced neurologists
based on individual patient data, clinically relevant
deficits and on the basis of imaging signs of early
ischemic damage on non-contrast computed tomogra-
phy (CT) according to the Alberta Stroke Program
Early CT Score (ASPECTS), posterior circulation-
ASPECTS and CTP. There was no pre-defined limit-
ing baseline infarct volume. Decision-making for IVT
and/or thrombectomy was a clinical decision in every
case.
Symptomatic intracerebral hemorrhage (sICH) was
defined according to ECASS-3 (any hemorrhage with
neurologic deterioration as indicated by an NIHSS
score that was 4 points higher than the value at base-
line or the lowest value in the first seven days or any
hemorrhage leading to death; in addition, the hemor-
rhage must have been identified as the predominant
cause of the neurologic deterioration) [19]. Functional
outcome was assessed using the modified Rankin
Scale (mRS) either by telephone calls or outpatient
visits. Clinical outcome was assumed as excellent if
the mRS score was 0–1 and good if the mRS score
was 0–2. An independent experienced interventional
neuroradiologist rated recanalization success based on
final angiograms according to the thrombolysis in
cerebral infarction score in anterior circulation. Suc-
cessful recanalization was defined as thrombolysis in
cerebral infarction score of 2b–3 [20].
Imaging data
Each patient underwent initial CT imaging including
non-contrast CT, CT angiography (CTA) and CTP.
An independent experienced neuroradiologist assessed
all images in a blinded and randomized fashion.
Between 18 and 36 h after IVT, each patient under-
went CT or MRI to rate the extent of an ischemic
lesion and to detect intracerebral hemorrhage. White
matter disease was identified according to the age-re-
lated white matter changes rating scale [21]. All CT
examinations were performed using one of the follow-
ing four CT scanners: SOMATOM Force, a 2 9 192
slice dual-source CT scanner; SOMATOM Definition
Flash, a 2 9 128 slice dual-source CT scanner;
SOMATOM Definition Edge and SOMATOM Defi-
nition AS+, both 128 slice CT scanners (all Siemens
Healthcare, Erlangen, Germany). For CTA, 50 mL of
iodinated contrast agent was administered intra-
venously, followed by a saline chaser of 40 mL, both
with a flow rate of 5 mL/s. CTA was performed from
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the aortic arch to the vertex with 140 and 80-kV tube
voltage and attenuation-based tube current modula-
tion (CareDose, Forchheim, Germany). Collimation
was 0.6 mm. CTA data were read as source images
using syngo.via imaging software (Siemens Health-
care). CTP was obtained with 0.6-mm collimation and
100-mm scan coverage in the z-axis using adaptive
spiral scanning. The datasets were acquired continu-
ously over 48 s (32 cycles, one sweep every 1.5 s).
Tube voltage and current were 80 kV and 200 mAs,
respectively. A total of 35 mL of iodinated contrast
agent (400 mg/mL) was administered at a flow rate of
5 mL/s, followed by a saline flush of 40 mL at 5 mL/s.
Analysis of CTP was based on the cerebral blood flow
(CBF) and cerebral blood volume (CBV) perfusion
maps. The CTP deficit according to the ASPECTS
topography was assessed for CBF and CBV maps as
previously described and used to assess CBF–CBV mis-
match [22]. In addition, mismatch was visually assessed
in 10% increments as routinely used clinically and as
previously described [23].
Statistics
Data were collected and evaluated using Excel (Micro-
soft, Redmond, WA, USA) spreadsheet software. Sta-
tistical analysis was performed using SPSS (IBM,
Armonk, NY, USA). Baseline characteristics, peri-
procedural time and outcome parameters were
analyzed. Groups were compared according to the dis-
tribution by using t-test, Mann–Whitney U-test or
chi-squared test. Differences were considered signifi-
cant if P < 0.05.
Ethics statement
This study was approved by the local ethics committee
(Faculty of Medicine at LMU Munich, project num-
ber 17-074) and was performed in accordance with the
ethical standards laid down in the 1964 Declaration of
Helsinki and its later amendments. Informed consent
was obtained.
Results
Of 545 patients treated with IVT from January 2015
to October 2018, 70 patients were included (mean
age  SD 77.6  11.5 years, 50.0% female). Median
National Institutes of Health Stroke Scale (NIHSS)
score on admission was 8.0 [interquartile range (IQR),
4–14] and median pre-morbid mRS score was 0 (IQR,
0–1). Patients’ baseline demographic, clinical and radi-
ological data are summarized in Table 1. The most
frequent reason for an extended time window was
Table 1 Baseline characteristics and treatment details
All patients (n = 70)
Age (years) 77.6  11.5
Sex – female 35 (50)
WUS with last seen well > 4.5 h 42 (60.0)
Onset unknown with last seen well > 4.5 h 9 (12.9)
Delayed hospital admission > 4.5 h 19 (27.1)
Drip and ship 3 (4.3)







Admission NIHSS score 8.0 (4.0–14.3)
Risk factors
Arterial hypertension 62 (88.6)
Diabetes mellitus 19 (27.1)
Hypercholesterolemia 14 (20.0)
Current smoking 12 (17.1)
Family history 3 (4.3)
Atrial fibrillation 28 (40.0)
Coronary heart disease 12 (17.1)
Peripheral artery disease 8 (11.4)
CHA2DS2-VASC score 6.0 (4.8–7.0)
Length of hospital stay (days) 7 (3.8–12.0)
Admission
blood pressure, systolic (mmHg) 162.2  24.9 (n = 64)
blood pressure, diastolic (mmHg) 87.2  15.8 (n = 60)
heart rate (bpm) 81.7  15.4 (n = 23)
Anterior circulation stroke 51 (72.9)
Posterior circulation stroke 16 (22.9)
Stroke mimic 3 (4.3)
Etiology
Cardioembolic 33 (49.3)
Large-vessel occlusion 10 (14.9)
Small-vessel disease 5 (7.5)
Embolic stroke of undetermined source 15 (22.4)
Unknown 4 (6.0)
Stroke mimic 3 (4.3)
IVT 70 (100)
rtPA dosage (/mg) 64.8  12.4
Large-vessel occlusion 42 (60.0)
MT 24 (34.3)
IVT, intravenous thrombolysis; MT, mechanical thrombectomy;
NIHSS, National Institutes of Health Stroke Scale; pmRS, pre-
morbid modified Rankin Scale; WUS, wake-up stroke. Data are
given as n (%), mean  SD and median (interquartile range). The
CHA2DS2-VASc score is a clinical prediction rule for estimating
the risk of stroke in patients with non-rheumatic atrial fibrillation
used to determine whether or not anticoagulation treatment is
required. The CHADS2 score is determined by adding the points
that corresponds to the conditions that are present in the patients
(C: congestive heart failure—1 point, H: hypertension–1 point, A:
Age ≥75 years—1 point, D: diabetes mellitus—1 point, S2: prior
stroke, TIA or thromboembolism—2 points). The CHA2DS2-
VASc score is a refinement of CHADS2 score and extends the
latter by including additional common stroke risk factors (age 65–
74, female gender and vascular disease. Furthermore “Age ≥75
years” has extra weight with 2 points). The maximum CHA2DS2-
VASc score is 9.
© 2019 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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WUS after awaking from sleep with stroke symptoms
(60.0%) followed by delayed hospital admission
(27.1%). A total of 75.7% of the patients showed
anterior circulation stroke symptoms. Large-vessel
occlusion was eminent in 42 patients (60.0%) and 24
patients also received endovascular treatment in addi-
tion to IVT. Median time between symptom recogni-
tion and hospital admission (‘door’) was 1.7 h and
between last seen well to door was 10.7 h, whereas it
was 2.5 and 11.4 h for administration of IVT, respec-
tively (Table 2).
Median ASPECTS and posterior circulation-
ASPECTS estimated on plain CT scans were each 10
(IQR, 9–10). On CTP images, median CTP mismatch
was 90% (IQR, 80%–100%). Median CBF-ASPECTS
was 6.5 (IQR, 3–9) and CBV-ASPECTS was 9.5
(IQR, 8–10) (Table 3). Three patients with stroke
mimics were treated in this study (one patient each
with vestibular neuropathy, peripheral radial palsy
and cerebral venous sinus thrombosis). sICH accord-
ing to ECASS-3 occurred in four patients (5.7%) and
adverse events other than sICH in five patients (7.1%)
(Table 4). In-hospital mortality was 11.4%. Median
NIHSS score at discharge was 3.0, which was signifi-
cantly different from NIHSS score at admission
(P < 0.001). There was a good clinical outcome at 3-
month follow-up in 49.3% and excellent clinical out-
come in 22.4% of patients. Median mRS score at
3 months was 3 (IQR, 2–5) (Fig. 1). Regarding
patients who underwent MT (n = 24), excellent clini-
cal outcome was achieved in two patients (8.3%) and
good clinical outcome in seven patients (29.2%).
Discussion
The aim of this study was to show real-life data in
patients treated with IVT and MT beyond the
Table 2 Time intervals in treated patients regarding hospital admis-
sion, intravenous thrombolysis (IVT) and mechanical thrombectomy
(MT)
All patients (n = 70)
Symptom recognition to door (min) 100.0 (67.8–175.3)
Last seen well to door (min) 639.0 (344.0–863.5)
Symptom recognition to IVT (min) 150.0 (110.0–262.5)
Last seen well to IVT (min) 685.0 (387.5–950.5)
Door to needle (min) 45.0 (38.0–59.5)
MT: Door to groin (min) 92.0 (79.3–110.8)
MT: Symptom recognition to groin (min) 174.5 (154.0–225.8)
MT: Symptom recognition to
revascularization (min)
279.0 (203.8–346.5)
MT: Last seen well to revascularization (min) 888.5 (802.0–1318.3)
Data are given as median (interquartile range).
Table 3 Imaging characteristics of patients
All patients (n = 70)
ASPECTS (data available in n = 53) 10 (9–10)
pc-ASPECTS (data available in n = 17) 10 (9–10)
CTP mismatch % 90 (80–100)
CBF-ASPECTS 6.5 (3–9)
CBV-ASPECTS 9.5 (8–10)
White matter disease 48 (68.6)
Old infarction in CT 26 (37.1)
ASPECTS, Alberta Stroke Program CT Score; CBF, cerebral blood
flow; CBV, cerebral blood volume; CT, computed tomography;
CTP, computed tomography perfusion; pc-ASPECTS, posterior cir-
culation-ASPECTS. Data are given as n (%) and median (interquar-
tile range).
Table 4 Peri-procedural and in-hospital complications
All patients (n = 70)
IVT, adverse eventsa 5 (7.1)
IVT, angioedemaa 1
IVT, other bleedinga 4




TICI 0 2 (8.3)
TICI 1 2 (8.3)
TICI 2a 1 (4.2)
TICI 2b 9 (37.5)
TICI 3 10 (41.7)
MT – peri-procedural complications
(groin hematoma)b
2 (8.3)
sICH (ECASS-3)a 4 (5.7)2 WUS patients








ICH, intracerebral hemorrhage; IVT, intravenous thrombolysis; MT,
mechanical thrombectomy; SAH, subarachnoid hemorrhage; sICH,
symptomatic intracerebral hemorrhage; TICI, thrombolysis in cere-
bral infarction; WUS, wake-up stroke. Data are given as n (%).
ECASS-3, any hemorrhage with neurologic deterioration as indi-
cated by an NIHSS score that was 4 points higher than the value at
baseline or the lowest value in the first seven days or any hemor-
rhage leading to death; in addition, the hemorrhage must have been
identified as the predominant cause of the neurologic deterioration
[19]. HI1, hemorrhagic infarction defined as small petechiae along
the margins of the infarct; HI2, as more confluent petechiae within
the infarcted area, but without space-occupying effect.
PH1, parenchymatous hematoma was defined as a clot not exceed-
ing 30% of the infarcted area with some mild space-occupying effect;
PH2, represented dense blood clot(s) exceeding 30% of the infarct
volume with significant space-occupying effect [24]. aData available
in n = 70 patients. bData available in n = 24 patients undergoing
MT.
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established time window of 4.5 h with decision-
making based on CTP. The main findings of this
study are as follows.
First, in patients with unknown onset, last seen well
of >4.5 h ago and an extended time window of
>4.5 h, patient selection for IVT, potentially in con-
junction with MT, can be safely performed based on
CTP. Median last seen well to hospital admission and
to IVT were 10.7 and 11.4 h, respectively. With
respect to time intervals, our study represents a differ-
ent study population compared with the EXTEND
trial with a median time from stroke onset to hospital
arrival of about 5.0 h and time from stroke onset to
IVT of about 7.0 h [15].
Secondly, the complication rate, especially regarding
sICH, does not exceed that in the approved time win-
dow <4.5 h for IVT after appropriate patient selection
with CTP. In the current study, sICH according to
ECASS-3 was observed in 5.7%, which is in line with
the sICH rate of 5.2% reported in clinical trials. In
the pooled analysis of ECASS, ATLANTIS, NINDS
and EPITHET trials, parenchymal hemorrhage was
seen in 5.2% [25]. Compared with this, the WAKE-
UP trial showed a rate of sICH of 2% [14], whereas
in the EXTEND trial sICH occurred in 6.2% [15].
Data from the Austrian Stroke Unit Registry
comparing WUS with stroke patients with known
symptom onset presented a rate of sICH of 4.1% [10].
Thirdly, this patient group can benefit from reperfu-
sion therapy. Median NIHSS score at discharge was
significantly different from NIHSS score on admis-
sion. Good clinical outcome at follow-up was seen in
49.3% and excellent clinical outcome in 22.4% of
patients. These results are within the range of the
nationwide Austrian Stroke Unit Registry reporting
51.9% good outcome at 3 months. In our study, 42
patients (60%) suffered from large-vessel occlusion
and 24 of these underwent MT with successful
recanalization in 19 patients and good clinical out-
come in 29.2%. Therefore, these real-life data regard-
ing MT in combination with IVT showed a lower rate
of good outcome than in DAWN and DEFUSE 3 tri-
als with good clinical outcome in 49% and 45%,
respectively [16,17]. However, in our study, we could
only present a small number of MT cases overall and,
in these trials, patients treated with thrombectomy fol-
lowing strict inclusion criteria.
In our study, we found that selected patients within
an extended time window beyond 4.5 h and treatment
with IVT (and MT) showed good clinical outcome
and no increase of adverse events, especially sICH.















0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
FOLLOW-UP 
DISCHARGE 
Modified Rankin Score at discharge and at 3 months follow-up 
0 1 2 3 4 5 6
Excellent clinical outcome  n = 15 (22.4%)  
Good clinical outcome   n = 33 (49.3%) 
Median mRS (IQR) 3.0 (2.0, 5.3)  
Median mRS (IQR) 3.0 (2.0, 5.0)  
Good clinical outcome  
Good clinical outcome  
analysis of n = 67 stroke patients   
without stroke mimics 
Figure 1 Functional outcome at discharge and at 3-month follow-up. IQR, interquartile range; mRS, modified Rankin Scale. Data
available in n = 70. [Colour figure can be viewed at wileyonlinelibrary.com]
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identifying those patients who can still benefit from
off-label IVT beyond the accepted time window of
4.5 h.
However, our study has some limitations. The data
describe only a single-center experience. Therefore,
treatment decisions were performed according to in-
house standards. Moreover, the study, although
including consecutive patients, is of an observational
character. Our study population represents only mod-
erate strokes with a median NIHSS score of 8 and
with significant penumbra. Thus, results cannot be
transferred to patients with other clinical and imaging
parameters. Due to the lack of a control group we
cannot make any conclusions about the efficacy of
IVT/MT in these selected patients. The examined
patient group is not completely homogenous. In
27.1% of patients the time window was certainly
longer than 4.5 h (known onset, delayed hospital
admission), the rest of the patients had WUS or
unknown symptom onset with a last seen well of
>4.5 h ago. Here, of course, stroke symptom onset
could have occurred within the permitted time win-
dow of 4.5 h. The strongest limitation is the lack of
comparison group and the treated patients cannot be
compared with the untreated patients.
Conclusions
In conclusion, among patients with an unknown and
extended time window and CTP findings consistent
with a small ischemic core, treatment with IVT seems
feasible and safe and may be effective. Therefore,
functional imaging including CTP may help to extend
the number of patients with acute stroke who can
benefit from further treatment. Randomized prospec-
tive comparisons of CTP- and MRI-based approaches
are therefore needed.
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